Company Description
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide.
The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine.
It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program.
The company was incorporated in 2018 and is based in Cincinnati, Ohio.
| Country | United States |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Neil J. Campbell MA, MBA |
Contact Details
Address: 201 East Fifth Street Cincinnati, Ohio United States | |
| Website | https://www.bluewatervaccines.com |
Stock Details
| Ticker Symbol | BWV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782107 |
| CUSIP Number | 09610B108 |
| ISIN Number | US09610B1089 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neil J. Campbell MA, MBA | President, Chief Executive Officer & Director |
| Joseph Hernandez M.S., MBA | Chief Executive Officer, Pres & Executive Chairman |
| Bruce Harmon | Chief Financial Officer |
| Jon M. Garfield | Chief Financial Officer & Interim Principal Executive Officer |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Dr. Ali I. Fattom Ph.D. | Head of Science & Discovery |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
| Dr. Ronald R. Cobb Ph.D. | Head of Science & Discovery |
| Erin Henderson | Chief Business Officer & Corporate Secretary |
| Frank A. Jaeger M.A., M.B.A. | Senior Vice President of Marketing & Business Development |
| James R. Sapirstein M.B.A., R.Ph. | Interim Executive Chairman |
| Theodore Scott Yoho | Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | PRE 14A | Filing |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 08, 2025 | 8-K | Current Report |
| Apr 03, 2025 | 8-K | Current Report |
| Apr 01, 2025 | NT 10-K | Filing |
| Mar 25, 2025 | 4 | Filing |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 3 | Filing |
| Feb 28, 2025 | 8-K | Current Report |